In order to investigate the safety and efficacy of sildenafil prescribed in primary care, a post-marketing surveillance study was undertaken. A total of 651 men with erectile dysfunction (ED) were enrolled from 31 family physicians in Korea from December 1999 to July 2002. Patients were regularly followed up to ascertain the safety and efficacy of sildenafil. Of the 651 patients enrolled, 572 (87.9%) returned for safety evaluation and efficacy assessment. In all, 458 (80.1%) of 572 patients reported improved erectile function with sildenafil. Hypertension, diabetes and low-dose sildenafil were associated with poor efficacy. A total of 71 adverse events were reported among 56 patients (8.6%), with the most frequent being hot flushes (5.6%), followed by headache (2.6%), palpitation (1.0%), anxiety (0.5%) and elevated ALT (0.5%). Only six patients (1.0%) discontinued sildenafil as a direct result of adverse events. These results suggest that sildenafil prescribed by primary care physicians was well tolerated and improved erectile function in patients with ED.
Introduction
Recent reports show that the prevalence of erectile dysfunction (ED) in Korea is similar to that in other countries. [1] [2] [3] In the nation's rural areas, where most of the residents are of older age, the average prevalence rate is 58.9%. 4 Moreover, 36.6% (32.2% after standardizing age) of outpatients seeking primary care showed symptoms of ED. 5 In addition, Korea is witnessing a rapid increase in the occurrence of cardiovascular diseases. Given that ED is usually linked with cardiovascular risk factors, 6 it is likely that the incidence of ED will increase in future and lead to the increased use of sildenafil for treatment of this condition. Recently published clinical trial results 7 showed that the efficacy and safety of sildenafil prescribed to Korean patients was similar to that reported in other countries. [8] [9] [10] However, the main focus of such trials was the efficacy of sildenafil prescribed in tertiary care facilities, such as in male health clinics and by urologists, and, as such, those results may differ from results in primary care institutions. 11 Moreover, trials on prescription patterns and follow-up trials on safety and efficacy of treatment after prescription in primary care settings are rarely conducted in Korea. The present study reports on a Post-Market Surveillance (PMS) survey conducted to investigate the adverse effects, efficacy and other relevant factors concerning sildenafil prescribed in primary care institutions.
Materials and methods

Study subjects
A total of 651 men over 20 y old with ED were enrolled from 31 family physicians from December 1999 to July 2002 in Korea. We enrolled consecutive patients with ED, who were newly prescribed sildenafil. Patients with unstable coronary artery disease and those receiving prescribed organic nitrate medication and sildenafil before this study were excluded.
Study design
This study was part of a sildenafil re-examination study, which was a prospective observational study performed after the launch of sildenafil. Patients were evaluated for efficacy, compliance and occurrence of adverse reactions at 4 and 12 weeks from the beginning of treatment. At each visit, patients were asked about dose, adverse clinical experiences, compliance and reasons for discontinuation if it occurred. For the safety assessment, physicians asked the question, 'have you experienced any discomfort with Sildenafil?', and recorded the occurrence of observed and patient-reported adverse events throughout the course of treatment. For the efficacy assessment, patients were asked to answer 'yes' or 'no' to the following questions: 'Did sildenafil boost your erection capability?' This re-examination study was approved by the Korea Food and Drug Administration and the Institutional Review Board of the Asan Medical Center, where the coordinating office is located.
Data collection and analysis
Patients' self-reported compliance and adverse reactions were all reconfirmed by the physician and recorded in the case record form (CRF). Standardized CRFs were completed by participating physicians. Each completed form was sent to a coordinating center of the Korea Post-Marketing Surveillance Research Group. Univariate analysis of category variables was performed using w 2 tests, and multivariate analysis by logistic regression. All variables significant in univariate analyses were included in the multivariate model. All analyses were carried out on a personal computer using SAS 6.12 software.
Results
Patient characteristics
Basic information was collected from 651 ED patients receiving sildenafil. These data showed that 42.4% of patients were in their 50s, 40.7% were obese with a body mass index (BMI) of 25 kg/m 2 or over, and 42.7% were current smokers (Table 1 ). In terms of ED, 12.9% reported that they had suffered from the condition for 6 months or less, 58.8% reported 6 months to 3 y and 28.3% reported 3 y or more. Hypertension was reported as the most common disease associated with ED, with a patient frequency of 36.3%. Other reported diseases included diabetes (23.7%), hyperlipidemia (12.9%), benign prostatic hyperplasia (7.1%) and fatty liver (6.5%). A sildenafil dose of 50 mg was used by 81.7% of patients, while 70.4% took sildenafil with other medications.
Efficacy of sildenafil
Of the 651 patients who made a first visit, 79 patients (12.1%) did not return for further treatment ( Figure 1 ). Of the 572 patients who did return, 421 (73.6%) answered that sildenafil was effective. The efficacy rate of 25, 50, and 100 mg sildenafil at the second visit was 59.8% (49/82), 75.1% (350/466) (Figure 1 ).
Factors associated with sildenafil efficacy
In single-variable analysis, patients suffering from hypertension or diabetes showed notably low sildenafil efficacy. As dosage was increased, sildenafil efficacy rose proportionally (Po0.05) ( 
Adverse events of sildenafil
Of the 572 patients who were followed up, 71 adverse events were experienced among 56 patients (8.6%) ( Table 3 ). The majority of adverse events (81.7%) were identified as mild, while one severe case involved headache (1.4%). Moderate adverse events were as follows: three cases of hot flush, two cases of palpitation and one case of each of the following: heaviness in the chest, headache, dysphagia, anxiety, insomnia and drowsiness. Of the 71 adverse events reported, whether mild, moderate or severe, hot flush (5.6%) was the most common, followed by headache (2.6%), palpitation (1.0%), anxiety (0.5%) and elevated ALT (0.5%). As for other adverse events, they were left as single occurrences. Of the 56 patients reporting adverse events, 12 (16.9%) discontinued treatment, while five patients (7.0%) had their dose reduced. In the majority (76.1%) of cases where adverse events were reported, no dose adjustments were made. By the end of the trial, six patients (1.0%) had discontinued treatment solely due to adverse events. No serious adverse events were reported during the trial.
Discussion
Existing studies on efficacy and safety of sildenafil generally asked questions regarding sexual intercourse, frequency of erection and erection sustainability, 12, 13 as outlined by the International Index of Erectile Function (IIEF) and the IIEF domain, and overall erection capacity (global efficacy questionnaire (GEQ)). Likewise, in this trial, an overall evaluation was made by asking the question, 'Did sildenafil boost your erection capability?'
Of the patients taking part in the present trial, 80.1% reported efficacious results. This result is similar to that published following the GEQ clinical trial led by Choi of Korea, 7 in which 81.2% of patients reported positive effects. The outcome is also similar to that reported in a meta-analysis by Fink et al, 14 showing that 86% of Asian men reported overall improvement in erection following sildenafil administration. Moreover, the result is similar to a US report 15 showing that 50 and 100 mg sildenafil resulted in improvements of erection in 77 and 84% of men, respectively, and a French report showing an improvement of erection in 79%. 16 Although the Fink study lacks information on African-American men, the findings suggest that sildenafil has similar efficacy among different races.
The present trial showed that a relatively small dose (25 mg) of sildenafil had less efficacy compared to higher doses. This, too, is similar to results of clinical trials conducted in Western countries 14, 15 and by Choi of Korea. 7 In the Choi study, it was found that only 1.5% of patients were on 25 mg sildenafil 53 days after initiation of the trial. Lower efficacy in patients suffering from diabetes was also found in Western studies. 17, 18 Although lower efficacy was reported in diabetic patients compared to nondiabetic patients, sildenafil was found to increase erectile function in diabetic patients when compared to diabetic patients taking a placebo. 19 The meta-analysis by Fink et al 14 indicated that sildenafil was less efficacious in patients aged more than 65, compared to younger patients. Although the present study indicated that age was not a factor in efficacy, we acknowledge this may have been due to the small number of patients aged over 65. While the efficacy in hypertension patients was similar to or lower than that in patients with normal blood pressure, it was higher than that in hypertension patients on placebo. 14, 17, 18, 20 The odds ratio showed that this decrease in efficacy was statistically significant in the present study.
The present study showed fewer cases of adverse events than other clinical trials, with approximately half of the patients taking part in clinical trials in other countries experiencing at least one adverse event.
14,15 Hot flushes and headaches were the most commonly reported adverse effect in Western studies, with 10-30% of patients reporting such symptoms. In other Korean studies, 32 and 23% of patients reported hot flushes and headaches, respectively. 7 In contrast, in the present study, figures ALT denotes alanine aminotransferase, CPK denotes creatinine phosphokinase.
Post-marketing surveillance study S Sunwoo et al for hot flush and headache were as low as 5.6 and 2.6%, respectively. This is largely due to the less stringent monitoring of adverse events compared to other clinical trials. Also, the outcome is probably attributable to the fact that the majority of patients in this study were suffering from other chronic illnesses or symptoms, and, as such, those diseases and the medication for them may have hidden or caused an underestimation of sildenafil-related adverse events. This relatively low reporting of adverse events has been observed in foreign clinical trials that are either open-ended or target primary care facilities. 11, 21 Our finding that very few patients discontinued treatment was in agreement with that of other trials. 11, 14, 20, 21 The current trial is not without limitations. First, there is no way to accurately determine how much the placebo effect improved erectile function. Second, because adverse events were measured using a questionnaire handed out during the patients' second visit, there is a high likelihood that occurrence of mild adverse events might have been underestimated. Third, the trial was incomplete in that the primary care facilities lost track of some patients, especially with the patients who failed to show effect of treatment. This would produce an overall higher false efficacy.
Despite the above limitations, the trial selected patients that visited 31 family physicians at various medical institutions nationwide, and as such the outcome is believed to be similar to that for patients visiting other primary care facilities. The sildenafil prescription pattern reported in this trial appears similar to that in other primary care facilities. Although there is a tendency to inflate the efficacy rate in the post-marketing surveillance due to the lack of a control group, this is unlikely to cause severe problems in estimating the overall efficacy of sildenafil prescribed in primary care facilities. Also, there is a possibility that mild adverse events may have been under-reported in the present study due to a recall bias; there is a low possibility of moderate to severe events under-reporting. Therefore, despite the above-mentioned limitations, the results of this trial provide useful information on the efficacy of sildenafil prescribed in primary care facilities, related factors that affect efficacy, and types and patterns of adverse events.
In summary, the efficacy of sildenafil identified through post-marketing surveillance studies conducted on outpatients in primary care facilities was 80%. Hypertension, diabetes and low-dose sildenafil showed poor efficacy. Although 71 adverse events were reported among 56 patients (8.6%), most were mild and only six patients (1.0%) discontinued treatment due to adverse events alone. As such, sildenafil showed high tolerability.
